До питання комплексної терапії ендометріозу

In: 2309-4117 · 2015 · W7112797699
OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex
⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-04 · read from full text ⓘ

This study investigated the morphological and immunohistochemical characteristics of endometriosis to improve antiproliferative treatment strategies. Researchers analyzed proliferation and apoptosis markers in patients with internal, external, and extragenital forms, finding that lesions exhibit low apoptosis and high proliferative activity. A subsequent phase assessed the drug Epigalin in 38 patients with adenomyosis and pain, comparing its efficacy against dienogest monotherapy. The results indicated that adding Epigalin effectively controls the proliferative potential of endometrial cells in these patients. This paper is centrally about endometriosis — specifically focusing on the role of adenomyosis and the use of antiproliferative agents like Epigalin for managing the condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Work on improving the quality of antiproliferative treatment of endometriosis with regard morphological and immunohistochemical data was performed.At the first phase of the study the activity of proliferation markers and apoptosis markers in patients with various forms of endometriosis were studies: in 35 patients with internal endometriosis (adenomyosis), 52 patients with external genital endometriosis and 19 patients with extragenital endometriosis. As a result, it was found that in the lesions of endometriosis there are low apoptosis, high cell proliferative activity and proliferative endometrium type is prevalent (endometrial hyperplasia).At the second phase of the study antiproliferative properties of drug Epigalin in the treatment of endometriosis were assessment. 38 patients with adenomyosis and marked pain syndrome participated in a study: 18 patients received dienogest and 20 patients received dienogest and administered Epigalin. The result revealed that Epigalin use in the treatment of endometriosis allows controlling proliferative potential of the endometrium cells.
Full text 5,102 characters · extracted from oa-html · click to expand
To the question of complex treatment of endometriosis DOI: https://doi.org/10.18370/2309-4117.2015.23.28-33Keywords: endometriosis, antiproliferative treatment, immunohistochemical studies, EpigalinAbstract Work on improving the quality of antiproliferative treatment of endometriosis with regard morphological and immunohistochemical data was performed. At the first phase of the study the activity of proliferation markers and apoptosis markers in patients with various forms of endometriosis were studies: in 35 patients with internal endometriosis (adenomyosis), 52 patients with external genital endometriosis and 19 patients with extragenital endometriosis. As a result, it was found that in the lesions of endometriosis there are low apoptosis, high cell proliferative activity and proliferative endometrium type is prevalent (endometrial hyperplasia). At the second phase of the study antiproliferative properties of drug Epigalin in the treatment of endometriosis were assessment. 38 patients with adenomyosis and marked pain syndrome participated in a study: 18 patients received dienogest and 20 patients received dienogest and administered Epigalin. The result revealed that Epigalin use in the treatment of endometriosis allows controlling proliferative potential of the endometrium cells. References - Adamyan, L.V., Kulakov, V.I. Endometriosis. Moscow. Medicine (1998): 317 p. - Kudrina, E.A., Ishchenko, A.I., Gadaeva, I.V., Shadyev, A.H., Kogan, E.A. “Molecular and biological characteristics of external genital endometriosis.” Obstetrics and gynecology, 6(2000): 24–27. - Sidorova, I.S., Kogan, E.A., Zayratiants, O.V., Unanian, A.L., Levakov, S.A. “A new look at the nature of endometriosis (adenomyosis).” Obstetrics and Gynecology, 3(2002): 32–38. - Tatarchuk, T.F., Kalugina, L.V. “Issue of prevention and treatment of hormonehyperproliferative diseases in women.” Women's Health, 7(2013): 51–57. - A shok, B.T., Chen, Y.G., Liu, X., Garikapaty, V.P., Seplowitz, R., et al. “Multiple molecular targets of indole-3carbinol, a chemopreventive anti-estrogen in breast cancer.” Eur J Cancer Prev, 11(2002): 86–93. - A uborn, K.L., Fan, S., Rosen, E.M., Goodwin L., et al. “Indole-3-carbinol is a negative regulator of estrogen.” J Nutr, 133(2003): 2470–2475. - C hatterji, U., Riby, J.E., Taniguchi, Т., Bjeldanes, E.X., et al. “Indole-3-carbinol stimulates transcription of the interferon gamma receptor 1 gene and augments interferon responsiveness in human breast cancer cells.” Carcinogeneses, 1 (Vol. 1) (2004): 119–1128. - Darai, E., Detchev, R., Hugol, D., Quang, N. T. “Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours.” Hum Reprod, 18(2003): 1681–1685. - Dmowski, W.P., Ding, J., Shen, J., Rana, N., Fernandez, B.B., Braun D.P. “Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis.” Hum Reprod, 16(2001): 1802–1808. - Firestone, G.L., Bjeldanes, L.F. “Indole-3-carbinol and З-З-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp 1 transcription factor interactions.” J Nutr, 133(2003): 2448–2455. - M asuda, M., Suzuki, M., Lim, J.T.E., Weinstein, I.E. “Epigallocatechin-3-gallate inhibits activation of HER -2/neu and downstream signaling pathways in human heat and neck and breast carcinoma cells.” Clin Cancer Res, 9(2003): 3486–3491. - R ahman, K.M., Aranha, O., Sarkar, F.H. “Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epitelial cells.” Nutr Cancer, 45(2003): 101–112. - R eed, G.A., Peterson, K.S., Smith, H.J., Gray, J.C., Sullivan, D.K., et al. “A phase I study of indole-3-carbinol in women: tolerability and effects.” Cancer Epidemiol Biomarkers Prev, 8(2005). - Scholzen, Т., Gerdes, J. “The Ki-67 protein: from the know and the unknown.” J Cell Physiol, 3(2000): 311–312. - Thangapazham, R.L., Singh, A.K., Sharma, A., et.al. “Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo.” Cancer Lett, 8(2007): 832–841. Downloads Published How to Cite Issue Section License Copyright (c) 2015 Н. Ф. Захаренко, Н. В. Коваленко, І. П. Маноляк This work is licensed under a Creative Commons Attribution 4.0 International License. Authors who publish with this journal agree to the following terms: - Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisadenomyosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK